OKUR – onkure therapeutics, inc. - class a (US:NASDAQ)
Stock Stats
News
OnKure Therapeutics (NASDAQ: OKUR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
OnKure to Present at the Stifel 2024 Healthcare Conference
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium [Yahoo! Finance]
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium
OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond [Seeking Alpha]
Form SC 13G/A OnKure Therapeutics, Filed by: TANG CAPITAL MANAGEMENT LLC
Form SC 13G OnKure Therapeutics, Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC
Form 424B3 OnKure Therapeutics,
Form 8-K OnKure Therapeutics, For: Nov 07
Form 10-Q OnKure Therapeutics, For: Sep 30
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.